Livraison suivie dans le monde entier | Env. 9–14 jours ouvrés

Votre panier

Votre panier est vide

Commencer à parcourir

Livraison gratuite pour les commandes de plus de €500.

Sous-total€0
Passer à la caisse
PerformancePréclinique uniquement

MOTS-C

Recherche publiée et base de preuves

MOTS-c is a 16-amino-acid microprotein encoded within the mitochondrial 12S rRNA gene that acts as a retrograde signalling molecule, with reported effects on AMPK signalling, folate-methionine one-carbon metabolism, and nuclear stress-response gene expression. Interventional data on administered MOTS-c come almost entirely from rodent and cell-culture studies, in which the peptide improved insulin sensitivity, mitochondrial respiration and exercise capacity. Human research to date is observational or genetic: circulating MOTS-c has been measured as a candidate biomarker across metabolic, cardiovascular, renal and reproductive conditions, and a mitochondrial variant in the MOTS-c coding region (m.1382A>C, K14Q) has been associated with type 2 diabetes risk in East Asian men. No controlled clinical trial has tested exogenous MOTS-c administration in humans, so efficacy and safety in people are not established.

En bref
  • MOTS-c est un peptide de 16 acides aminés codé dans l'ADN mitochondrial.
  • Des études animales ont rapporté une meilleure sensibilité à l'insuline.
  • Aucun essai contrôlé ne l'a testé chez l'humain.

18 études · 13 depuis 2023 · plus récente 2026

Études citées
18
Publiées 2023+
13
Article le plus récent
2026
Dernière révision
oct. 2026

Thèmes récurrents dans la littérature

  • AMPK activation
  • mitochondrial-derived peptide (mitokine)
  • insulin sensitivity and glucose tolerance
  • exercise-induced expression and skeletal muscle function
  • Nrf2 and oxidative stress signalling
  • retrograde mitochondrial-to-nuclear signalling
  • circulating biomarker in metabolic and cardiovascular disease
  • m.1382A>C (K14Q) mitochondrial polymorphism
  • mitochondrial biogenesis and PGC-1alpha
  • ageing and physical decline

Identifiants du composé

CAS
1627580-64-6
PubChem
146675088

Statut réglementaire

Recommandé par un comité consultatif de la FDA.

Le 23–24 July 2026, le comité consultatif sur la préparation pharmaceutique de la FDA a examiné MOTS-C pour la liste 503A Bulks et a recommandé son ajout lors d'un vote rapporté de 7–5 with two abstentions. Recommended on a divided vote, despite there being no interventional human administration study of the compound.

Ce n'est pas une approbation. Le comité conseille ; il ne décide pas. La recommandation n'est pas contraignante, la FDA n'a pas terminé la réglementation qui changerait formellement quoi que ce soit, et l'inclusion dans la liste 503A Bulks n'équivaut pas à l'approbation FDA d'un médicament. La liste régit également la préparation pharmaceutique pour les patients, qui est une activité distincte de la fourniture à usage de recherche uniquement.

Ce que le vote consultatif de juillet 2026 a réellement accompli décrit le processus, les autres composés examinés et les quatre choses que le vote est régulièrement mal interprété comme signifiant.

Identité chimique

Ce qu'est MOTS-C, chimiquement.

Formule moléculaire
C101H152N28O22S2
Masse moléculaire
2174.6 g/mol
Numéro CAS
1627580-64-6
PubChem CID
146675088

Ces chiffres proviennent de la fiche PubChem pour ce composé et décrivent la base libre. Le peptide lyophilisé est normalement fourni sous forme de sel d'acétate ou de trifluoroacétate et contient de l'eau résiduelle, donc la masse de poudre dans un flacon ne correspond pas à la quantité suggérée par la masse moléculaire ci-dessus. La pureté chromatographique sur un certificat d'analyse ne résout pas cette différence non plus — comment lire un certificat d'analyse explique pourquoi.

Les preuves

18 études publiées.

Classées par rigueur du protocole d'étude, puis par date. Chaque entrée renvoie à sa source pour que les résultats puissent être vérifiés dans l'article plutôt que pris sur parole.

  1. 01Revue systématique2024

    The correlation between mitochondrial derived peptide (MDP) and metabolic states: a systematic review and meta-analysis

    Zhou Q, et al. · Diabetology & Metabolic Syndrome · Systematic review and meta-analysis of 7 studies, 602 participants

    Pooled analysis reported lower circulating MOTS-c concentrations in participants with diabetes or obesity overall, but subgroup analysis showed the direction differed: reduced in diabetes and increased in obesity. The authors noted small study numbers and heterogeneity in assay methods.

  2. 02Clinique humaine2026

    Systemic MOTS-c levels are increased in adults with obesity in association with metabolic dysregulation and remain unchanged after weight loss

    Yoon SH, et al. · Journal of Clinical & Translational Endocrinology · Cross-sectional comparison of 22 lean and 32 adults with obesity, with 10 followed after bariatric surgery weight loss

    Circulating MOTS-c was higher in adults with obesity and showed a biphasic relationship with HOMA-IR. Levels did not change after surgical weight loss despite improvements in other metabolic measures.

  3. 03Clinique humaine2026

    Reduced serum and skeletal muscle MOTS c levels in women with polycystic ovary syndrome are associated with mitochondrial dysfunction

    Kutuk IS, et al. · Scientific Reports · 40 women with polycystic ovary syndrome versus 40 age- and BMI-matched controls; serum and skeletal muscle sampling

    Women with PCOS had lower serum MOTS-c than controls (220.2 versus 498.3 pg/mL) alongside reduced skeletal muscle expression. The findings were correlational and did not test MOTS-c administration.

  4. 04Clinique humaine2026

    Circulating mitochondrial-derived microproteins at rest and in response to an acute bout of endurance exercise in individuals with cerebral palsy

    Horwath O, et al. · Experimental Physiology · Typically developing adults, typically developing adolescents, and adults with cerebral palsy (GMFCS II-IV); acute endurance exercise bout

    Resting circulating mitochondrial-derived microprotein levels, including MOTS-c, were comparable between adults with cerebral palsy and typically developing groups despite lower muscle mass and fitness. Acute endurance exercise produced only minimal changes in circulating levels in all groups.

  5. 05Clinique humaine2025

    Repeated Heat Stress Modulates the Levels of the Mitokines MOTS-C and FGF21 in Active Men during Calf Muscle Immobilization

    Elhusseiny R, et al. · Medicine and Science in Sports and Exercise · Randomised controlled trial, 19 physically active men, 2 weeks of calf immobilization with or without repeated heat treatment

    Repeated heat treatment during limb immobilization was associated with higher circulating MOTS-c compared with immobilization alone. The trial measured endogenous mitokine responses rather than administering MOTS-c.

  6. 06Clinique humaine2025

    Circulating Mitochondrial Open Reading Frame of the 12S Ribosomal RNA Type-c Is Higher in Acute Coronary Syndrome

    Cao P, et al. · Journal of the American Heart Association · Case-control study, 400 participants: normal controls, unstable angina, acute myocardial infarction

    Circulating MOTS-c was higher in acute coronary syndrome than in controls and discriminated cases with a reported sensitivity of 0.890. A MOTS-c to oxidative stress marker ratio was associated with major adverse cardiac events after myocardial infarction.

  7. 07Clinique humaine2024

    Effects of empagliflozin and dapagliflozin on serum humanin, MOTS-c levels, nitrosative stress, and ferroptosis parameters in diabetic patients with heart failure

    Asil H, et al. · European Journal of Pharmacology · 74 patients with diabetes and heart failure receiving SGLT2 inhibitors, 37 healthy controls

    SGLT2-inhibitor treatment was associated with significantly higher serum MOTS-c levels and reduced nitrosative stress and ferroptosis markers relative to baseline. The study measured endogenous MOTS-c as a response marker and did not administer the peptide.

  8. 08Clinique humaine2021

    A pro-diabetogenic mtDNA polymorphism in the mitochondrial-derived peptide, MOTS-c

    Zempo H, et al. · Aging (Albany NY) · Meta-analysis of three East Asian cohorts (J-MICC, Multiethnic Cohort, Tohoku Medical Megabank), n = 27,527; plus mouse and in vitro work

    The East-Asian-specific m.1382A>C variant, which produces a K14Q substitution in MOTS-c, was associated with higher type 2 diabetes prevalence in men but not women, with the association concentrated in men with low physical activity. K14Q-MOTS-c showed diminished insulin-sensitising activity in vitro and in high-fat-fed mice.

  9. 09Clinique humaine2021

    Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humans.

    von Walden F, et al. · J Appl Physiol (1985) · randomised trial, n=30 healthy adults (endurance, resistance or control), single session with muscle biopsies and blood sampling

    Circulating humanin rose after a single endurance session but not after resistance exercise; plasma MOTS-c showed only a non-significant trend to increase after endurance exercise. Plasma mitochondrial-derived peptide levels were not correlated with VO2max, leg strength or muscle mtDNA copy number.

  10. 10Animal in vivo2026

    MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1α/AMPK-dependent manner

    Gudiksen A, et al. · Free Radical Biology and Medicine · Two transgenic mouse strains (PGC-1alpha and AMPK models) given MOTS-c; skeletal muscle mitochondrial bioenergetics

    MOTS-c administration improved intrinsic skeletal muscle mitochondrial bioenergetic performance and reduced oxidative stress markers without increasing respiratory protein content. The effects depended on intact PGC-1alpha and AMPK signalling in the mouse models.

  11. 11Animal in vivo2025

    Mitochondrial-encoded peptide MOTS-c prevents pancreatic islet cell senescence to delay diabetes

    Kong BS, et al. · Experimental & Molecular Medicine · Aged C57BL/6 mice and non-obese diabetic mice treated with MOTS-c; human serum comparison

    MOTS-c treatment reduced markers of pancreatic islet cell senescence and improved glucose intolerance in the mouse models. The authors also reported lower circulating MOTS-c in people with type 2 diabetes than in healthy controls.

  12. 12Animal in vivo2025

    Endurance training enhances skeletal muscle mitochondrial respiration by promoting MOTS-c secretion

    Feng Y, et al. · Free Radical Biology and Medicine · Endurance-trained versus sedentary mice, with a comparison of marathon runners and sedentary individuals

    Endurance training increased MOTS-c secretion and skeletal muscle mitochondrial respiratory function in mice. Human sampling showed higher MOTS-c in trained runners than sedentary participants, an association rather than an intervention result.

  13. 13Animal in vivo2024

    MOTS-c modulates skeletal muscle function by directly binding and activating CK2

    Kumagai H, et al. · iScience · Cell-free binding assays, cultured muscle and adipose cells, mouse muscle atrophy models, with human cohort genotype analysis

    MOTS-c was shown to bind casein kinase 2 (CK2) directly, activating it in skeletal muscle while suppressing it in adipose tissue. The K14Q variant peptide showed altered activity, and the corresponding genotype was examined for disease association in human cohorts.

  14. 14Animal in vivo2021

    MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis

    Reynolds JC, et al. · Nature Communications · Young, middle-aged and old mice given MOTS-c; supporting human exercise sampling

    MOTS-c administration improved physical performance in young, middle-aged and old mice and altered muscle metabolic gene expression. In humans, acute exercise was associated with increased endogenous MOTS-c expression in skeletal muscle and plasma.

  15. 15Animal in vivo2015

    The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance

    Lee C, et al. · Cell Metabolism · Mice (high-fat diet and aged), plus cell culture; MOTS-c administration

    The paper described MOTS-c as a mitochondrial-encoded peptide that targets the folate-methionine one-carbon cycle and activates AMPK. In mice, MOTS-c administration prevented age-dependent and high-fat-diet-induced insulin resistance and diet-induced obesity.

  16. 16In vitro2026

    MOTS-c is a mitochondrial-encoded interferon-linked host defense peptide.

    Rice MC, et al. · Elife · bacterial assays, human monocytes, primary mouse macrophages and a mouse MRSA peritonitis model

    MOTS-c showed direct antibacterial activity against E. coli and MRSA partly via membrane targeting, neutralised MRSA infectivity in a mouse peritonitis model, was induced in human monocytes by interferon-gamma and LPS, and reprogrammed differentiating mouse monocytes toward macrophages with altered antigen-presentation and interferon signatures.

  17. 17In vitro2018

    The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress.

    Kim KH, et al. · Cell Metab · cell culture and mouse studies of MOTS-c localisation under metabolic stress

    MOTS-c translocated to the nucleus under glucose restriction in an AMPK-dependent manner, regulated a broad set of nuclear genes including those with antioxidant response elements, and interacted with stress-responsive transcription factors such as NRF2.

  18. 18Revue2026

    Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance

    Mendias CL, Awan TM · Sports Medicine · Narrative review of approved and unapproved peptides used in sports medicine, including mitochondrial-derived peptides

    The review found that many unapproved peptides, including mitochondrial-derived peptides, show favourable tissue-repair or metabolic outcomes in animal models. It concluded that rigorous human safety and efficacy data for these compounds remain scarce.

Limites

Ce que ces preuves n'établissent pas.

No randomised controlled trial has administered exogenous MOTS-c to humans, so dosing, pharmacokinetics, long-term safety and any functional benefit in people are unestablished. Human data are limited to observational biomarker associations and one mitochondrial genotype association, and circulating MOTS-c moves in opposite directions across conditions (lower in diabetes, higher in obesity and acute coronary syndrome), so its interpretation as a marker is not settled; assay standardisation is also inconsistent between studies.

Questions courantes sur la recherche.

What is MOTS-C?

MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded by a short open reading frame inside the mitochondrial 12S rRNA gene. It is studied as a retrograde signalling molecule linking mitochondrial status to nuclear gene expression.

Why is MOTS-C described as an exercise-responsive peptide?

Because endogenous expression tracks with exercise. The cited Nature Communications work reports that exercise induces MOTS-c expression in human skeletal muscle and circulation, which is why the peptide is studied alongside exercise-adaptation pathways such as AMPK.

How does MOTS-C relate to other mitochondrial-derived peptides?

It sits in the same family as humanin and the SHLP peptides, all encoded within mitochondrial DNA rather than the nuclear genome. The cited reviews compare their signalling roles; MOTS-c is the member most closely associated in the literature with the folate–AICAR–AMPK axis.

Disponible dans notre catalogue

À des fins de recherche uniquement. Non destiné à la consommation humaine, au diagnostic, au traitement ou à la prévention de toute condition. Rien sur cette page ne constitue un avis médical, et aucune étude résumée ici ne doit être considérée comme une recommandation.